All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1118P"
1118P - Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
- Almudena García-Castaño (Santander, Spain)
Abstract
Background
Melanoma in elderly patients has different features, and this population has higher risk of comorbidities. Efficacy and safety of D+T have been well established in 2 clinical phase III trials, however limited data has been reported for the elderly population. This study analyzes the real world care of patients with advanced melanoma treated with D+T in Spain, focused on the elderly population.
Methods
We performed a retrospective descriptive analysis of elderly (≥75 years old, y.o.) and non-elderly (<75y.o.) BRAFV600+ advanced melanoma patients treated with D+T or D monotherapy in 10 Spanish academic centers. Clinical variables, safety, and efficacy of both groups were compared. Influence of variables on the initial dose and safety was analyzed by univariate and multivariate analysis.
Results
159 patients were included, 130 <75y.o. and 29 ≥75y.o. Clinical features were similar between groups, except in number of comorbidities, number of metastatic sites, ECOG-PS, and BRAFV600 mutation type. 5 patients per group received D monotherapy (p=0.019) and this decision was only influenced by age. There were no differences in adverse events (AE) rate or grade between groups. However, pyrexia was more frequent in patients <75y.o. (42.3% vs 13.8%, p=0.005) while asthenia was more frequent in the elderly group (44.8% vs 25.4%, p=0.044). Besides, AE management was different: 83.5% of AEs in <75 y.o were treated without D or T modifications vs 64.5% in the elderly (p<0.001). Overall, ≥75y.o. patients had more D dose modifications (22.3 vs 41.4%, p=0.039), lower initial dose of T (p=0.005), more T interruptions (26.4 vs 50%; p=0.029) and less D and T dose intensity (p=0.018 and p=0.020). There were no differences in efficacy between groups, with a response rate, median progression-free survival and overall survival of 63.8%, 8.6 and 22.3 months in <75y.o. vs 62%, 10.3 and 29.1 months in ≥75 y.o.
Conclusions
D+T is safe and effective in ≥75 y.o. patients with advanced BRAF600+ melanoma. AE management is different in this population compared to <75 y.o. patients. Differences in AE profile as the lower rate of pyrexia in elderly patients should be confirmed in future studies.
Legal entity responsible for the study
Novartis.
Funding
Novartis.
Disclosure
A. García-Castaño: Advisory/Consultancy, Speaker Bureau/Expert testimony: Pierre-Fabre; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Sharp & Dohme; Advisory/Consultancy, Speaker Bureau/Expert testimony: Sanofi; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck. I. González-Barrallo: Advisory/Consultancy: Novartis; Advisory/Consultancy: Bristol-Myers Squibb; Research grant/Funding (institution), Clinical trial costs: Merck Sharp & Dohme. J. Medina Martínez: Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: Merck Sharp & Dohme. J.L. Manzano Mozo: Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pierre-Fabre; Advisory/Consultancy: Roche; Advisory/Consultancy: Merck Sharp & Dohme; Advisory/Consultancy: Amgen; Advisory/Consultancy: Merck. M. Majem Tarruella: Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Non-remunerated activity/ies: Merck Sharp & Dohme; Advisory/Consultancy, Non-remunerated activity/ies: Boehringer Ingelheim; Advisory/Consultancy, Non-remunerated activity/ies: AstraZeneca; Advisory/Consultancy, Non-remunerated activity/ies: Roche; Advisory/Consultancy: Kyowa Kyrin; Advisory/Consultancy: Pierre-Fabre. C. Aguado de La Rosa: Advisory/Consultancy, Non-remunerated activity/ies: Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Sanofi; Non-remunerated activity/ies: Novartis; Advisory/Consultancy: Pierre-Fabre; Advisory/Consultancy: Merck Sharp & Dohme; Advisory/Consultancy: Bristol-Myers Squibb. I. Palacio: Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy, Travel/Accommodation/Expenses: GlaxoSmithKline. L. Osterloh: Full/Part-time employment: Novartis. A. Martinez Fernandez: Full/Part-time employment: Novartis. All other authors have declared no conflicts of interest.